Pfizer predicts €21bn in global sales from its Covid-19 vaccine this year          

The company raised its forecast for 2021 Covid-19 vaccine sales by more than 70% to €21.5bn and said demand from governments around the world trying to halt the pandemic could contribute to its growth for years to come.

Revenue from the vaccine – developed with German partner BioNTech – is expected to account for more than one third of Pfizer's full-year sales this year. File picture: Larry Cummins

Pfizer raised its forecast for 2021 Covid-19 vaccine sales by more than 70% to $26bn (€21.5bn) and said demand from governments around the world trying to halt the pandemic could contribute to its growth for years to come.

The company said it expects by the end of this month to file for full approval of the vaccine for people over the age of 16 in the US, where it is currently only authorised for emergency use.